Indeed, studies on pharmacogenetic predictors of the efficacy of MPH for treating ADHD have demonstrated that gene polymorphisms, including SLC6A2, SLC6A3, COMT, DRD4, ADRA2A, and SNAP-25, may be related to the efficacy of MPH (Gomez-Sanchez et al., 2017; Myer et al., 2018). The gene discussed is SNAP25; the disease is attention deficit-hyperactivity disorder.